Engineering Psychedelics: $22M Pool For Clinical Trials Of Compounds Targeting CNS Disorders
NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing.
